ATE376001T1 - Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung - Google Patents

Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung

Info

Publication number
ATE376001T1
ATE376001T1 AT03793572T AT03793572T ATE376001T1 AT E376001 T1 ATE376001 T1 AT E376001T1 AT 03793572 T AT03793572 T AT 03793572T AT 03793572 T AT03793572 T AT 03793572T AT E376001 T1 ATE376001 T1 AT E376001T1
Authority
AT
Austria
Prior art keywords
protein
thrombolytic
anticolotting
actions
linker peptide
Prior art date
Application number
AT03793572T
Other languages
German (de)
English (en)
Inventor
Bingxing Shi
Zuze Wu
Aiping Yu
Chunna Dong
Original Assignee
Inst Radiation Med Amms Pla
Beijing Lu Yin Li Hua Pharmace
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Radiation Med Amms Pla, Beijing Lu Yin Li Hua Pharmace filed Critical Inst Radiation Med Amms Pla
Application granted granted Critical
Publication of ATE376001T1 publication Critical patent/ATE376001T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03793572T 2002-09-03 2003-09-03 Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung ATE376001T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA021290865A CN1480466A (zh) 2002-09-03 2002-09-03 一类溶栓抗凝双功能融合蛋白及应用

Publications (1)

Publication Number Publication Date
ATE376001T1 true ATE376001T1 (de) 2007-11-15

Family

ID=31954566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03793572T ATE376001T1 (de) 2002-09-03 2003-09-03 Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung

Country Status (8)

Country Link
US (1) US8212003B2 (enExample)
EP (1) EP1541589B1 (enExample)
JP (2) JP2006516113A (enExample)
CN (2) CN1480466A (enExample)
AT (1) ATE376001T1 (enExample)
AU (1) AU2003261606A1 (enExample)
DE (1) DE60316967T2 (enExample)
WO (1) WO2004022598A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102443065A (zh) * 2005-06-01 2012-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用
CN1896108B (zh) * 2005-06-01 2012-01-04 中国人民解放军军事医学科学院放射与辐射医学研究所 特异性抗凝血物质的制备及其应用
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8968728B2 (en) * 2006-05-12 2015-03-03 Bharat Biotech International Limited Chimeric fusion proteins
ATE533789T1 (de) 2006-12-15 2011-12-15 Inst Radiation Med Amms Pla Herstellung von mit geringen blutungen assoziiertem gerinnungshemmendem fusionsprotein und dessen verwendung
CN100519585C (zh) * 2007-02-06 2009-07-29 中国人民解放军军事医学科学院基础医学研究所 P11与sak的融合蛋白及其制备方法和用途
JP2010518039A (ja) * 2007-02-12 2010-05-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
PT3078743T (pt) * 2007-09-28 2020-07-15 Portola Pharm Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
DE102009010611A1 (de) * 2009-02-25 2010-08-26 Siemens Aktiengesellschaft Vorrichtung und Verfahren zur Steuerung einer mit mehreren Brennern ausgestatteten Turbine für flüssige oder gasförmige Brennstoffe
JP6234224B2 (ja) * 2010-08-05 2017-11-22 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 血栓溶解及び抗凝固特性を有するタンパク質融合構築物
CN102180973B (zh) * 2011-03-18 2012-08-29 重庆大学 靶向多功能防栓融合蛋白及其制备方法和应用
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
CN106366200B (zh) * 2015-07-23 2020-04-10 武汉光谷人福生物医药有限公司 制备重组葡激酶-水蛭素融合蛋白的方法
JP7028904B2 (ja) * 2019-03-21 2022-03-02 アカデミア シニカ 合成ペプチド、それを備える薬学的組成物及び血栓塞栓症関連疾患の治療におけるその使用
CN113150168B (zh) * 2021-01-29 2022-11-11 武汉真福医药股份有限公司 一种qk纤溶酶基因-水蛭素融合蛋白的制备方法及应用
KR102789819B1 (ko) * 2021-10-21 2025-03-31 중앙대학교 산학협력단 트롬빈 검출용 신규한 펩타이드 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5759542A (en) * 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6423680B1 (en) * 1998-10-30 2002-07-23 Hsc Research And Development Limited Partnership Inhibitor of platelet activating factor
CN1188522C (zh) * 2001-07-20 2005-02-09 健力福生化技术（上海）有限公司 一种血栓靶向性溶栓蛋白表达质粒及其构建
CN1181099C (zh) * 2002-07-23 2004-12-22 中国人民解放军第二军医大学 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB

Also Published As

Publication number Publication date
CN1301268C (zh) 2007-02-21
DE60316967T2 (de) 2008-05-08
US20060127389A1 (en) 2006-06-15
CN1480466A (zh) 2004-03-10
US8212003B2 (en) 2012-07-03
CN1678636A (zh) 2005-10-05
EP1541589B1 (en) 2007-10-17
EP1541589A1 (en) 2005-06-15
DE60316967D1 (de) 2007-11-29
JP2006516113A (ja) 2006-06-22
EP1541589A4 (en) 2005-11-16
JP2010184930A (ja) 2010-08-26
WO2004022598A1 (fr) 2004-03-18
AU2003261606A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
ATE376001T1 (de) Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DE502004012225D1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
NO20053872D0 (no) Fusjonskonstruksjoner og anvendelse av disse for fremstilling av antistoffer med okt FC-reseptorbindingsaffinitet og effektorfunksjon.
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
Wetsel et al. Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments.
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
DE10075010I1 (de) Fusionsproteine mit immunglobulinanteilen ihre Herstellung und Verwendung
DE602004022800D1 (de) Gerinnungsfaktor-fc chimere proteine zur behandlung von hämophilie
MY154826A (en) Fusion protein capable of binding vegf
ATE486934T1 (de) Das shiga-ähnliche toxin enthaltende, rekombinante proteine und vaskuläre, endothel- spezifische wachstumsfaktorfragmente
DE60114018D1 (de) Von zellen präsentierte peptide
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
Essex et al. Protein disulfide isomerase catalyzes the formation of disulfide-linked complexes of vitronectin with thrombin− antithrombin
DK1636261T3 (da) Thrombopoietinproteiner med forbedrede egenskaber
Schmidtchen Chronic ulcers: a method for sampling and analysis of wound fluid
WO2007132481A3 (en) Novel thrombolytic molecules and a process therefor
DE69634994D1 (de) Bindegewebe-wachstumsfaktor 3.
RU2008108806A (ru) Набор лиофилизированного тромбина и лиофилизированного фибриногена, используемый для приготовления фибриновой мембраны, и его применение
CN1286262A (zh) 人胎盘抗凝蛋白介导的新型抗凝蛋白
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
Fischer et al. Purification of recombinant human coagulation factors II and IX and protein S expressed in recombinant Vaccinia virus-infected Vero cells
Liu et al. End-point modification of recombinant thrombomodulin with enhanced stability and anticoagulant activity
Zhong Role of the first epidermal growth factor-like domain in factor IX function.
Kang et al. Visualization of low molecular weight factor VIII purified in the presence of benzamidine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties